OrganOx Ltd.

$1.5 billion acquisition strengthens global leadership in organ technology and accelerates progress toward making every organ countOXFORD, England and MADISON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- OrganOx Ltd. today announced the completion of its acquisition by Terumo Corporation, following satisfaction of all customary regulatory and closing conditions. OrganOx is now a wholly owned subsidiary of Terumo, positioning the company to unlock new opportunities to evolve its technology and reach more patients worldwide. As first announced on August 25, 2025, the acquisition combines OrganOx’s pioneering organ perfusion technology with Terumo’s global scale and expertise in medical innovation. “The global need for donor organs remains urgent, with thousands of patients each year dying while waiting for a transplant or facing the risk of a failed transplant,” said Craig Marshall, CEO of OrganOx. “Our mission has always been to create a world where every organ counts. Joining Terumo will accelerate our ability to scale our operations more rapidly, enter new markets and ensure that more patients around the globe can benefit from our technologies.” The acquisition will enable investment in research and development efforts, including the evolution of the OrganOx metra® platform technology beyond liver transplantation. It will also enable the company to capitalize on opportunities to expand the use of normothermic machine perfusion (NMP) for organ support and enhancement. In addition to advancing innovations, OrganOx will benefit from Terumo’s extensive global network to accelerate commercial expansion, deepening its presence in existing regions and opening access to new markets worldwide. Marshall added, “This milestone reflects the extraordinary dedication of our team, whose commitment to innovation and patient outcomes brought OrganOx to this point. With Terumo’s partnership, we’re positioned to deliver even greater growth and impact.” About OrganOxOrganOx is a commercial stage organ technology company, spun out of the University of Oxford in 2008, dedicated to developing technologies to improve outcomes for patients with acute or chronic organ failure. The OrganOx metra® is a normothermic machine perfusion (NMP) platform approved in the U.S., Europe, Canada, and Australia. It has been utilized in over 6,000 liver transplants to date to keep donor livers in a metabolically active state outside the body enabling longer preservation times and functional assessment of the organ prior to transplant, leading to an increased number of organs available for transplant. Learn more at www.organox.com. About Terumo CorporationTerumo (TSE: 4543) is a global medical innovation company. Guided by an unwavering commitment to patients, and driven by the passion of our associates, we strive to fulfill our Group Mission of “Contributing to Society through Healthcare.” Founded in Tokyo in 1921, we provide a comprehensive range of solutions in the fields of therapeutic procedures, hospital operations, and life sciences in more than 160 countries and regions. OrganOx Media:Nicole SloanMarketing Communications and PR Managernicole.sloan@organox.com

A new report from JP Morgan, in partnership with Dealforma, has proven that medtech mergers and IPOs are alive and well in 2025. The Q3 ‘25 Biopharma & Medtech Licensing and Venture Report , published at the beginning of October, highlights the latest activity in medtech, from funding rounds to capital raised. Medtech IPO and M&A activity in Q3 handily surpassed full-year numbers in 2024, according to the report, signaling a high amount of interest in the space. “The IPO market has had a challenging year broadly across healthcare. Medtech has been the bright spot in life sciences, certainly over biotech, for IPOs,” Kathryn McDonough, Head of Life Sciences of J.P. Morgan’s Innovation Economy business and a key contributor to the report, told MD+DI. “It's a combination of broader macro and investment thesis considerations, and if you look at medtech IPOs that have been done, they are closer to going EBITDA positive than the cohort before them, they are coming in with strong syndicates, which shows public investors that they have that backing, they have that support of capital.” There were 67 medtech venture rounds in Q3, totaling $2.9 billion and bringing the 2025 year-to-date total to $9.5 billion across 259 rounds. In addition, four medtech IPOs raised $568 million on NASDAQ and NYSE in Q3 2025, bringing the 2025 year-to-date IPO volume to $1.5 billion across seven offerings of $15 million+ on U.S. exchanges. This is a considerable number, especially considering that there were no medtech IPOs in 2023, and just four in all of 2024. “If you think about public investors and what they are looking for for their funds and how they operate, medtech provides revenue opportunities and is soon to be cash flow positive. It's an easier, more palatable investment thesis for a public investor. Biotech has a longer runway to commercialization to break even or become EBITDA positive,” McDonough said. “I think people are still scrutinizing the fundamentals of a business so they are going to be picking investments accordingly. Strong syndicate, near cashflow positive as medtech usually have revenues, and a faster trajectory to more of a cash flow generative business.” Medtech M&A activity saw a huge uptick in Q3, with 65 transactions, the most active quarter since 2022. Those transactions totaled $21.7 billion in upfront cash and equity, the second-highest quarterly value over the same period. Median M&A upfront payments rose to $177 million. Some notable Q3 M&A includes Waters Corp's merger with Becton Dickinson's Biosciences & Diagnostic Solutions business for approximately $17.5 billion,Terumo Corp’s acquisition of OrganOx for $1.5 billion, and ArchiMed Group’s acquisition of ZimVie Inc. for $730 million. McDonough told MD+DI that she’s hopeful this trend will continue in 2026. “I'm hoping it's going to continue on the current trajectory. We have a lot of larger medtech companies that are looking at opportunities. These larger companies are always looking to develop their pipelines and products through acquisitions, and I hope that will continue” she said. “It's also a lot to do with what private companies are looking at in terms of how founders are seeing an exit strategy for themselves. Are they looking to go public, or are they looking to build and sell? I think it'll be healthy. All of the micro factors you want in place exist, and it's the macro uncertainty that is plaguing everyone in any sector right now. You have high interest rates, tariff concerns, supply chain concerns. Within the micro segment, things are ready to go.” While some investments boomed, medtech licensing partnerships and venture funding struggled to surpass previous years in Q3. A total of 21 medtech licensing partnership deals were announced, totaling $7.9 billion, with over $126 million in upfront payments. The 2025 year-to-date total reached $10.1 billion, with $376 million committed upfront. That represents 4% of total deal value, tied for the second-smallest upfront share in nearly a decade. Analysts blame risk aversion for the drop. Though medtech venture funding was up quarter-over-quarter in Q3, it has seen a decline year-over-year. The sector has still attracted some meaningful interest from venture investors, with $9.5 billion raised across 259 rounds year-to-date. Another change highlighted by this year’s report shows a potential shift in life science and medtech hotspots geographically. Two markets attracted the majority of medtech venture investment in the U.S. in the last year– $4.4B across 89 rounds in the Bay Area in 2024-25 and $2.6B across 53 rounds in the same timeframe in Boston. San Francisco is now outpacing Boston in what is known as an ongoing rivalry between the two life science-focused hubs. “I think it's no secret that you have a lot of AI concentration in San Francisco. It is an ongoing healthy rivalry in the life sciences space, but I have to believe the concentration of AI and tech in the Bay Area is contributing to the change,” McDonough told MD+DI. Medtech is a continuously changing beast, as new developments come onto the market rapidly and investors fight to keep up. While rapid change is possible across all industries, this report signals a strong 2025 for medtech financially, and sets the industry up for more growth and development in 2026. “Within medtech it’s the general trend of, things are happening faster and innovation is continuing to improve efficiencies and processes that exist within the medtech space,” McDonough said. “We are seeing the convergence of health tech and tech in the medtech and the tools and diagnostic spaces. It's a really interesting time to be in this space, whether you are doing cash management or you are a founder or scientist. The innovation taking place is really cool, and it is great to be a part of and seeing what companies are doing. It's great to be along for the ride.”

全球医疗行业每日重点资讯 文 | 苏丁 企业动态 和黄医药公告，董事会获悉公司执行董事苏慰国因健康理由将暂停履行首席执行官的职务。有鉴于此，董事会已委任公司执行董事兼首席财务官郑泽锋担任代理首席执行官一职，即时生效。 联影集团已签约在武汉光谷建设全球创新高端医疗装备智造基地。这是联影落户湖北12年后的一次重量级追投。这一高端医疗装备智造基地将建设六大项目：外科诊疗装备整机与核心部件攻关与产业化基地项目；精密科学仪器国产化产业基地项目；医疗智能体与元医院数智化场景研发基地项目。自2013年重仓湖北、在光谷设立武汉总部以来，联影已累计投入超70亿元，其中研发投入超50亿元。 西门子医疗与韩国庆尚北道浦项市达成一项合作。西门子医疗计划在2026年至2027年间，向浦项科技园投入210亿韩元（约合人民币1.08亿元），用于在9800平方米的园区内扩建超声心动图的生产设施。该扩建项目完成后，西门子医疗的超声心动图设备年产能预计将从目前的50万台提升至100万台，并新增超过400个就业岗位。 赛默飞世尔科技（Thermo Fisher Scientific）启用位于北卡罗来纳州的一家高度自动化的制造工厂。该工厂占地37.5万平方英尺，每周可生产超过4000万个移液器吸头。该公司表示，位于梅班（Mebane）的该工厂每12秒可生产96个吸头，每小时可生产5000个成品组件。该工厂还配备了自动化的包装和运输设备。预计该工厂将提供约100个工作岗位，涵盖生产、工程和业务运营，目前已聘用了约40人。诺和诺德迎来一项重磅人事任命。Filip K. Knop已正式出任高级副总裁，并同时担任新成立的医学与转化科学（M&TS）部门负责人。此外，他将从10月1日起接过公司首席医疗官的接力棒，接替即将退休的Stephen Gough，开启在诺和诺德的全新征程。 日本医疗器械生产商泰尔茂(Terumo)已同意以约15亿美元收购英国器官保存设备生产商OrganOx有限公司。此项收购将增强泰尔茂在器官保存技术领域的能力，标志着其战略性进入器官移植领域。 吉利德科学公司（Gilead Sciences）以3.5亿美元收购了CAR-T疗法开发商Interius BioTherapeutics。将Interius整合入吉利德专注于细胞疗法的子公司Kite，为该制药公司提供一个体内平台，旨在在患者体内生成CAR-T细胞。Kite称，此举旨在“通过将DNA插入患者基因组，提供更持久和长效的治疗效果”。吉利德已获批的两款CAR-T疗法，均为传统体外疗法。相比之下，Interius的创新型即用型且个性化方案旨在通过单次静脉输注给药，无需预处理化疗和复杂的细胞处理流程。 聚焦实体瘤耐药治疗的创新药研发公司应世生物InxMed Limited宣布完成超3400万美元的C轮融资，本轮融资由复健资本领投，比邻星创投、澄翔资本、昆仑资本投资，老股东恩然创投继续追加投资。 信华生物药业（广州）有限公司完成数千万美元A+轮系列融资，杏泽资本领投。资金将主要用于推动公司核心管线进入全球临床试验阶段，加速首创新药（FIC）和同类最佳药（BIC）的研发进程。 南京迈诺威医药完成亿元级B轮融资，由知名投资机构IDG资本独家领投，老股东元禾原点持续跟投。本轮融资将重点用于加速创新药研发管线推进，以及旗下核心产品 “蓉芷” 溶脂针剂的市场推广与销售布局。 蚂蚁集团与北京大学第三医院达成战略合作，正式成立AI医疗联合创新实验室，将整合双方临床诊疗与专业大模型方面的优势，在多个科室内，开展医疗多模态大模型、人工智能辅助临床诊疗等技术研发与应用研究，推动AI医疗应用落地。 迪哲医药发布2025半年报。报告期内，公司实现营业收入3.55亿元，较上年度同比增长74.4%。公司净亏损持续缩窄，同比下降12%。公司账上现金及现金等价物达22.51亿元。 沛嘉医疗发布截至2025年6月30日止六个月的中期业绩。报告期内，本集团实现总收入人民币3.53亿元，较2024年同期增长17.3%。集团整体经营亏损收窄19.4%，为人民币6832万元。若剔除前沿技术业务相应实体整体亏损的影响，本集团期内核心业务净亏损为人民币3072万元，同比大幅收窄52.4%。 深圳微芯生物科技股份有限公司发布2025年半年度报告：上半年营收4.07亿元，同比增速提升至34.56%；归属于上市公司股东的净利润2959.22万元，业绩扭亏为盈。 复宏汉霖发布2025年中期业绩，公司2025上半年实现营收28.195亿元人民币，同比增长2.7%；净利润3.901亿元，经营性现金流超7.709亿元，同比增长206.8%，持续正向流入。 产业动态 百济神州公告称，公司及其全资子公司百济神州瑞士与RoyaltyPharma签订《特许权使用费购买协议》，RoyaltyPharma同意在交割时支付8.85亿美元，购买百济神州瑞士就单克隆抗体Imdelltra（Tarlatamab）在中国以外地区年度销售净收入收取中个位数百分比特许权使用费的大部分权利。此外，百济神州瑞士有权在2026年8月25日前出售额外的收取特许权使用费的权利，最高可获6500万美元额外付款。 艾伯维同意以高达12亿美元的价格收购Gilgamesh Pharmaceuticals旗下一款实验性抗抑郁治疗药物。根据协议条款，艾伯维将收购Gilgamesh的核心候选药物bretisilocin，该药物正在开发用于治疗重度抑郁症。同时，Gilgamesh将把其其他研发项目剥离，组建一家新的实体公司—— Gilgamesh Pharma Inc.。 Jazz Pharmaceuticals与Saniona宣布，两家公司已达成全球许可协议，后者将授予Jazz对SAN2355的全球独家开发权。SAN2355是一种具有差异性的钾通道激活剂，主要用于癫痫及其他潜在适应症的开发，旨在克服非选择性Kv7靶向化合物的局限性。根据协议条款，Jazz将负责主导并资助SAN2355的进一步开发、监管申报及全球商业化活动。Jazz将预先支付4250万美元，并有望支付高达1.925亿美元的开发和监管里程碑款项。此外，Saniona还有资格获得高达8亿美元的商业里程碑款项，以及从个位数到两位数不等的净销售额分级特许权使用费，总计约10亿美元。 由东软集团旗下的创新公司东软医疗，自主研发的NeuViz P10碲锌镉光子计数CT正式获得国家药品监督管理局（NMPA）批准上市。这不仅是中国首台光子计数CT，也是全球首台8cm宽体光子计数CT。 信达生物宣布其自主研发的全球首创PD-1/IL-2α-bias双特异性抗体融合蛋白IBI363的首个全球III期临床研究（MarsLight-11）的新药临床试验申请（IND）获美国食品药品监督管理局（FDA）批准，用于治疗免疫耐药的鳞状非小细胞肺癌（NSCLC）患者，标志着这一创新性双免疫疗法的全球开发取得重要进展。 由晨泰医药支持，中国肺癌领域权威专家吴一龙教授牵头开展的“佐利替尼真实世界研究者会暨肺癌脑转移高峰论坛”在广州召开。会上宣布，全球首个针对EGFR阳性伴脑转移非小细胞肺癌（NSCLC）患者的多中心前瞻性真实世界研究（RWS）正式启动。佐利替尼真实世界研究，采用创新的“以患者为中心”研究设计，预计纳入800例患者，覆盖全国多家顶尖医疗中心，旨在为肺癌脑转移诊疗提供高级别真实世界证据，推动临床实践优化。 NMPA官网显示，轩竹生物/先声药业1类新药地罗阿克获批上市，单药适用于未经过间变性淋巴瘤激酶（ALK）抑制剂治疗的 ALK 阳性的局部晚期或转移性非小细胞肺癌（NSCLC）患者的治疗。 联系美通社 +86-10-5953 9500 info@prnasia.com